Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer.

Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, Arap W, Hajitou A.

Mol Cancer Ther. 2009 Aug;8(8):2383-91. doi: 10.1158/1535-7163.MCT-09-0110. Epub 2009 Aug 11.

2.

Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.

Preuss E, Muik A, Weber K, Otte J, von Laer D, Fehse B.

J Mol Med (Berl). 2011 Nov;89(11):1113-24. doi: 10.1007/s00109-011-0777-8. Epub 2011 Jun 23.

PMID:
21698427
4.

Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.

Kia A, Przystal JM, Nianiaris N, Mazarakis ND, Mintz PJ, Hajitou A.

Mol Cancer Ther. 2012 Dec;11(12):2566-77. doi: 10.1158/1535-7163.MCT-12-0587. Epub 2012 Oct 10.

5.

Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.

Tang Q, Zhang D, Wan M, Jin L.

Cancer Biother Radiopharm. 2007 Dec;22(6):755-61.

PMID:
18158766
6.

Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.

Ardiani A, Sanchez-Bonilla M, Black ME.

Cancer Gene Ther. 2010 Feb;17(2):86-96. doi: 10.1038/cgt.2009.60. Epub 2009 Sep 18.

7.

Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.

Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, Nicholas T, Kruse CA.

Cancer Gene Ther. 2002 Jan;9(1):87-95.

9.

Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects.

Nicholas TW, Read SB, Burrows FJ, Kruse CA.

Histol Histopathol. 2003 Apr;18(2):495-507. doi: 10.14670/HH-18.495. Review.

PMID:
12647801
10.

Bystander effect in glioma suicide gene therapy using bone marrow stromal cells.

Li S, Gu C, Gao Y, Amano S, Koizumi S, Tokuyama T, Namba H.

Stem Cell Res. 2012 Nov;9(3):270-6. doi: 10.1016/j.scr.2012.08.002. Epub 2012 Aug 22.

11.

Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells.

Yang L, Chiang Y, Lenz HJ, Danenberg KD, Spears CP, Gordon EM, Anderson WF, Parekh D.

Hum Gene Ther. 1998 Mar 20;9(5):719-28.

PMID:
9551619
12.

Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery.

Tanaka M, Fraizer GC, De La Cerda J, Cristiano RJ, Liebert M, Grossman HB.

Gene Ther. 2001 Jan;8(2):139-48.

13.

Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy.

Jimenez T, Fox WP, Naus CC, Galipeau J, Belliveau DJ.

Cell Commun Adhes. 2006 Jan-Apr;13(1-2):79-92.

PMID:
16613782
14.
15.
17.

Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene.

Asklund T, Appelskog IB, Ammerpohl O, Langmoen IA, Dilber MS, Aints A, Ekström TJ, Almqvist PM.

Exp Cell Res. 2003 Apr 1;284(2):185-95.

PMID:
12651152
18.

A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect.

Princen F, Robe P, Lechanteur C, Mesnil M, Rigo JM, Gielen J, Merville MP, Bours V.

Clin Cancer Res. 1999 Nov;5(11):3639-44.

19.

In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.

Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T, Ajalli R, Wildner O, Morris J, Kume A, Hamada H, Blaese RM, Ozawa K.

J Gene Med. 2004 Mar;6(3):288-99.

PMID:
15026990
20.

Ultrasound-targeted HSVtk and Timp3 gene delivery for synergistically enhanced antitumor effects in hepatoma.

Yu BF, Wu J, Zhang Y, Sung HW, Xie J, Li RK.

Cancer Gene Ther. 2013 May;20(5):290-7. doi: 10.1038/cgt.2013.19. Epub 2013 Apr 19.

PMID:
23598435

Supplemental Content

Support Center